Definitive Healthcare Corp. (DH), operating through its various subsidiaries, offers specialized commercial intelligence solutions for the U.S. healthcare industry. The company's services furnish essential data on healthcare providers and their activities, enabling clients to navigate critical business processes, from the early stages of product development to strategic market entry planning and effective sales and marketing execution. Its sophisticated platform incorporates sixteen distinct intelligence modules. These modules are designed to support key functional domains such as sales optimization, marketing initiatives, clinical research, new product creation, strategic planning, human capital acquisition, and the oversight of physician networks. Definitive Healthcare caters to a broad spectrum of clients, including biopharmaceutical firms, medical device manufacturers, healthcare information technology companies, and direct healthcare providers. Additionally, its clientele extends to diverse organizations within the wider healthcare ecosystem, such as staffing and commercial real estate companies, financial institutions, and other related entities. Founded in 2011, Definitive Healthcare Corp. is headquartered in Framingham, Massachusetts.
Definitive Healthcare Reports Financial Results for Second Quarter 2026
Definitive Healthcare reported Q2 revenue of $55.2 million, down 9% year-over-year, while Adjusted EBITDA fell to $14.6 million from $18.7 million in the prior year.
The company issued FY 2026 revenue guidance of $220.0 million to $222.0 million and Q3 revenue guidance of $54.0 million to $55.0 million, reflecting the continued revenue decline despite meeting internal targets.
Management highlighted improvements in net dollar retention and the launch of 'Turbo', a new AI-powered platform, as key steps toward returning to growth.